Lonza

streetinsider. | December 20, 2016

After the close, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced it has entered into a long-term agreement with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). This agreement follows a successful multi-year clinical manufacturing relationship where the companies have been refining the process and analytical methods to produce clinical and commercial supplies of voclosporin....

Pharama Tech | December 21, 2016

Aurinia Pharmaceuticals announced on Dec. 19, 2016 that the company has entered into a long-term agreement with Lonza for the manufacture of voclosporin API. This agreement follows a multi-year clinical manufacturing relationship where the companies have refined the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza will produce cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis (LN)...

Nasdqa | December 23, 2016

Research and Markets has announced the addition of the "Global Pharmaceutical Contract Manufacturing Market 2016-2020" report to their offering. The global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical dru...

RegistrarDaily | December 27, 2016

The Contract Pharmaceutical Manufacturing market report covers forecast and analysis for the Contract Pharmaceutical Manufacturing market on a global and regional level. The Contract Pharmaceutical Manufacturing industry report provides historic data of 2015 along with a Contract Pharmaceutical Manufacturing market forecast from 2015 to 2021 based on Contract Pharmaceutical Manufacturing industry volume and Contract Pharmaceutical Manufacturing revenue (USD Million)....